Related Experiment Videos
L-5-hydroxytryptophan can prevent nociceptive disorders in man.
1Interuniversity Centre of Neurochemistry, Florence, Italy.
Advances in Experimental Medicine and Biology
|March 18, 2000
Summary
L-5-Hydroxytryptophan (L-5-HTP) significantly reduced migraine frequency in a placebo-controlled study. This marks the first evidence suggesting L-5-HTP can alter central nervous system mechanisms in individuals prone to headaches.
Area of Science:
- Neurology
- Neuroscience
- Pain Management
Background:
- Primary pain conditions, such as migraine, represent a significant public health concern.
- Effective prevention strategies for primary pain are limited, highlighting a need for novel therapeutic approaches.
Purpose of the Study:
- To investigate the efficacy of L-5-Hydroxytryptophan (L-5-HTP) in preventing migraine, the most common primary headache disorder.
- To explore the potential of L-5-HTP to modify underlying central nervous system (CNS) abnormalities associated with migraine predisposition.
Main Methods:
- A prospective, long-term, placebo-controlled study design was employed.
- Participants predisposed to headaches received either L-5-HTP or a placebo.
- Migraine incidence and frequency were monitored over the study duration.
Main Results:
- L-5-HTP administration resulted in a statistically significant reduction in the occurrence of migraines.
- This study provides the initial data demonstrating L-5-HTP's potential in migraine prevention.
Conclusions:
- L-5-HTP shows promise as a preventative treatment for migraine.
- The findings suggest that L-5-HTP may modulate CNS mechanisms implicated in migraine pathophysiology in susceptible individuals.